Invivyd, Inc. (IVVD)
(Delayed Data from NSDQ)
$0.80 USD
+0.04 (5.88%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.80 0.00 (0.26%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IVVD 0.80 +0.04(5.88%)
Will IVVD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IVVD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IVVD
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
IVVD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates
Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?
Other News for IVVD
Invivyd (IVVD) Welcomes New Expert to SPEAR Study Group | IVVD Stock News
Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for ...
Invivyd announces addition of Iwasaki to SPEAR Study Group
Invivyd (IVVD) Gains Momentum with New Monoclonal Antibody Guidelines | IVVD Stock News